Omeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a report published on Wednesday.

OMER has been the subject of several other research reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Thursday, November 14th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Finally, Rodman & Renshaw began coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price for the company. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Price Performance

Shares of NASDAQ:OMER opened at $6.03 on Wednesday. The firm’s 50 day simple moving average is $4.24 and its two-hundred day simple moving average is $4.14. Omeros has a 1-year low of $1.60 and a 1-year high of $7.51.

Institutional Trading of Omeros

A number of large investors have recently added to or reduced their stakes in OMER. Vanguard Group Inc. grew its stake in shares of Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after buying an additional 81,348 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Omeros in the 3rd quarter valued at about $305,000. Barclays PLC lifted its holdings in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 51,873 shares during the last quarter. Bank of New York Mellon Corp grew its position in Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 31,081 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Omeros during the second quarter worth approximately $105,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.